Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
about
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Anti-GD2 immunotherapy for neuroblastoma.Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
P2860
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
@en
type
label
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
@en
prefLabel
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
@en
P2860
P1476
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
@en
P2093
Jaume Mora
P2860
P304
P356
10.1586/17512433.2016.1160775
P407
P577
2016-03-02T00:00:00Z